If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Steroid hormones are converted from their parent compound, cholesterol. Mammalian steroid hormones can be grouped into five groups by the receptors to which they bind: glucocorticoids, mineralocorticoids, androgens, estrogens, and progestogens. Some forms of vitamin D, such as calcitriol, are steroid-like and bind to homologous receptors, but lack the characteristic fused ring structure of true steroids.
The origin and first recorded use of the term megacap (or any of its various spellings), in relation to stock capitalization, is unclear. It dates back to at least 1997, if not earlier. The S&P 100 was launched on June 15, 1983. The Russell Top 200 Index was launched on September 1, 1992. The Fidelity Mega Cap Stock Fund's inception was on December 28, 1998. The Russell Top 50 Mega Cap Index was launched on January 1, 2005. Also in 2005, investment advisory executive Richard Imperiale noted that some investors were classifying "the top 10 percent of companies by market cap" into a mega cap segment of the stock market. In 2009, the third edition of Stock Investing For Dummies defined mega caps (and ultra caps) as companies with market caps over $50 billion. Subsequent editions used that definition until 2020, when the sixth edition redefined them as having market caps over $200 billion. The 2023 version, retitled Investing in Stocks For Dummies, used the same definition as the sixth edition. The Morningstar US Mega Cap Index was established on March 31, 2011. In 2011, Investing Demystified defined mega-caps as companies with market caps of at least $25 billion, whereas in the same year, The Complete Idiot's Guide to Stock Investing defined them as having market caps at least $50 billion. That's equivalent to $34 billion and $69 billion, respectively, in 2024 using GDP deflator adjustment. In 2014, Asset Allocation Demystified stated that a typical mega cap company had a market cap of over $50 billion. The S&P 500 Top 50 Index was launched on November 30, 2015.
No human pathogens of comparable virulence have yet emerged from marine species. In 2024 aquaculture production was concentrated in Asia which accounted for around 89% of global aquatic animal aquaculture production, followed by Latin America and the Caribbean (3%), Europe (2%), Africa (2%), Northern America (0.4%) and Oceania (0.2%). The top five countries together produced 82% of the total output; China, Indonesia, India, Viet Nam and Bangladesh. Freshwater systems dominate aquaculture production of aquatic animals, accounting for 64 million tonnes (63%), compared to 38 million tonnes (37%) from marine and coastal systems. Biological control methods to manage parasites are already being used, such as cleaner fish (e.g. lumpsuckers and wrasse) to control sea lice populations in salmon farming. Models are being used to help with spatial planning and siting of fish farms in order to minimize impact.
Sources: en.wikipedia.org
In relation to this, MDMA's duration and the offset of its effects appear to be determined more by rapid acute tolerance rather than by circulating drug concentrations. Similar findings have been made for amphetamine and methamphetamine. One mechanism by which tolerance to MDMA may occur is internalization of the serotonin transporter (SERT). Although MDMA and serotonin are not significant TAAR1 agonists in humans, TAAR1 activation by MDMA may result in SERT internalization, for instance in rodents in whom MDMA is a potent TAAR1 agonist. It is thought that brain serotonin levels are depleted after MDMA administration but that levels typically return to normal within 24 to 48 hours.
== Awards, distinctions and memberships == 2000: Ernst Bloch Promotional Award for his book Gott ist schön. Das ästhetische Erleben des Koran [Godi s Beautiful. The Aesthetic Experience of the Koran] (1999) 2003: Annual Prize of the Helga-und-Edzard-Reuter-Foundation 2004: Schwarzkopf-Europe-Prize of the Foundation Schwarzkopf-Stiftung Junges Europa 2007: Member of the Deutsche Akademie für Sprache und Dichtung 2008: Fellowship of the Villa Massimo in Rom 2009: Hessian Cultural Prize 2011: Nomination of the novel Dein Name for the German Book Prize 2011: Buber-Rosenzweig-Medal 2011: Hannah Arendt Prize; Award Presentation Speech: Marie Luise Knott 2012: Kleist Prize for the novel Dein Name (2011) 2012: Honorary Prize of the City of Cologne Culture Prize Kölner Kulturpreises 2012: Cicero Prize for public speaking 2014: Gerty Spies Literature Prize 2014: Prize of the Association of German Institutions of Dialogue des BDDI 2014: Joseph Breitbach Prize 2015: North Rhine-Westphalian Academy of Sciences, Humanities and the Arts, Member 2015: Peace Prize of the German Publishers' Association 2015: Jan Michalski Prize for Literature finalist for Zwischen Koran und Kafka: West-östliche Erkundungen 2016: Marion Dönhoff Prize for International Understanding and Reconciliation 2017: Hermann Sinsheimer Prize of the City of Freinsheim 2017: ECF Princess Margriet Award for Culture of the European Cultural Foundation 2017: Civic Engagement Award of the German Newspaper Publishers, Award Presentation Speech: Wolf Lepenies 2017: State Prize of the Federal State North Rhine-Westphalia, Award Presentation Speech: Wolfgang Schäuble 2018: Samuel Bogumil Linde Prize; Award Presentation Speech: Joachim Gauck 2020: Friedrich-Hölderlin-Preis 2021: Appointed Honorary Member of the Board of Trustees of the WDR Symphony Orchestra Cologne 2021: Austrian Book Publishers Award for Tolerance in Thought and Action 2022: Honorary Degree of the Philosophy Department of the University of Siegen 2023: Member of the authors association PEN Berlin 2023: Winfried Prize of the City of Fulda 2023: Hans Ehrenberg Prize 2024: Thomas Mann Prize 2026: Bundesverdienstkreuz 1. Klasse
== Awards and honours == In 1987, he was awarded the Royal Society of Chemistry medal for Analytical Separations and in 1991, was awarded the Martin Medal by the Chromatographic Society. In 1993 he received the Gold Medal of the Society of Analytical Chemistry. The International Mass Spectrometry Society awarded him the J.J.Thomson Medal in 1997, and in 1999 he received the A.J.Evans Medal from Cardiff University. He was a past Chairman of the BMSS, served on the SERC Chemistry Committee as Chairman of the Instrumentation Panel and also on NERC, MRC and AFRC panels. He was a former Joint Editor-in-Chief of Biomedical and Environmental Mass Spectrometry.
Sources: en.wikipedia.org
each holding with equality only when a = b = c. This says that in the non-equilateral case the harmonic mean of the sides is less than their geometric mean, which in turn is less than their arithmetic mean, and which in turn is less than their quadratic mean.
The diver needs to stay on the bottom to work some of the time, and may need to have neutral buoyancy some of the time. The diving suit is usually buoyant, so added weight is usually necessary. This can be provided in several ways. Unwanted positive buoyancy is dangerous to a diver who may need to spend significant time decompressing during the ascent, so the weights are usually attached securely to prevent accidental loss.
Jean Yee Hwa Yang is an Australian statistician known for her work on variance reduction for microarrays, and for inferring proteins from mass spectrometry data. Yang is a Professor in the School of Mathematics and Statistics at the University of Sydney.
== Development == Episode Two was the second in a planned trilogy of shorter episodic games that would continue the story of Half-Life 2 (2004). It was developed simultaneously with Episode One (2006) by a team led by David Speyrer. This schedule of simultaneous development aided them in streamlining the story between the two games to create an immersive story. The technology used was the same for both games, allowing the development teams to quickly fix any technical problems that might arise from either game; this happened often because of the multi-platform release. The team originally planned the ending to feature a comical sequence with Lamarr, Kleiner's pet headcrab, floating in space outside the rocket Gordon launches into space; however, Valve president Gabe Newell requested killing off a major character to create a cliffhanger for Episode Three. On July 13, 2006, Valve announced that Episode Two would be released on Xbox 360 and PlayStation 3 in addition to Windows. Valve handled the development for the PC and Xbox 360, while Electronic Arts (EA) worked on the PlayStation 3 version. It was announced on September 7, 2007, that the PlayStation 3 version would be delayed because the EA studio behind the game was in the United Kingdom, away from Valve's development team, and therefore lagged behind in its schedule. According to Valve's marketing director, Doug Lombardi, the Xbox 360, PlayStation 3 and Windows versions would be identical in functionality and performance. An audio commentary is also featured, as in Episode One and Lost Coast.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.